1. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding

2. Program Goals

3. Control Blood Glucose Levels to Prevent or Delay the Onset of Complications

4. HbA1c = Fasting Blood Glucose and Postprandial Glucose

11. Type 1 Diabetes Clinical Trial: MKC-171

12. Study Design

13. Inhaler Device: Gen2 vs MedTone

15. Mean Change in HbA1c From Baseline to Week 24

16. Mean Change in HbA1c Levels From Screening to Week 24

17. Mean Change in Body Weight From Baseline to Week 24

18. Adverse Events

19. Severe Hypoglycemia Event Rates

20. Cough Over Time

21. Mean FEV1 From Baseline to Week 24

22. Type 2 Diabetes Clinical Trial -- MKC-175: Study Design

24. Average Daily Insulin Dose and Mean Change in HbA1c Level From Baseline to Week 24

25. Mean 7-Point Glucose Measurements at Baseline and at Week 24

26. Change in Body Weight From Baseline to Week 24

27. Most Common Adverse Event and Rates of Hypoglycemic Events

28. Patients With New-Onset Cough

29. Mean FEV1 From Baseline to Week 24

30. Type 2 Diabetes Clinical Trial -- MKC-102: Study Design

31. Hypoglycemia and Weight Change

32. Black Box Warning

33. Closing Comments: Role of Inhaled Insulin

34. Abbreviations

35. References

36. References (cont)

37. References (cont)